Cardiovascular

LivaNova CFO Thad Huston's resignation comes as activist investor PrimeStone Capital has been urging the company to make some big changes. Hiring a new CFO was, in fact, one of those changes.

The Salt Lake City, UT-based company won FDA approval to expand a clinical study of the Tria surgical aortic valve. The company raised $20 million in a series D round in June.

A medtech analyst suggests that the sum of LivaNova's parts are worth significantly more than its current value, and that value could be created by breaking up the company.

Pressed for time? Here's the medtech news you need most, in one minute or less.

The structural heart leader expects to see double-digit growth in transcatheter aortic valve replacement (TAVR) sales next year.

This marks the sixth FDA clearance the NY-based company has received.

Study findings point out the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority for the primary hierarchical efficacy endpoint.

These are the companies in the private sector that medtech analysts have called attention to in 2020.

Results from the SCOPE II trial were presented at TCT Connect and showed the Acurate Neo failed to demonstrate non-inferiority when compared to Medtronic’s CoreValve Evolut.